| Obesity Heightens Risk Of Death From Prostate Cancer
Overweight or obese men, according to a new US study, are at greater risk of dying from prostate cancer after treatment than men who are thin. The study, conducted by Dr. Jason Efstathiou and colleagues, published in the journal Cancer, says that overweight or obese men are at a substantially higher risk of death within five years of diagnosis. Overweight men with some extra fat had a 52 percent higher risk of death from locally advanced prostate cancer, the study reports, while obesity more than doubled the likelihood at 64 percent. The study followed 788 patients diagnosed with advanced prostate cancer over a period of eight years, examining the relationship between BMI (body mass index) and mortality. Of the randomized patient pool, 241 were considered at normal body weight, 402 were overweight, and 145 were clinically obese.
Goulet hospitalized for lung ailment
LOS ANGELES, Oct. 21 Famed Las Vegas entertainer Robert Goulet is hospitalized in Los Angeles after being diagnosed with pulmonary fibrosis, a report said.
The Las Vegas Review-Journal reported Sunday the 73-year-old singer was admitted to Los Angeles' Cedars-Sinai Medical Center for treatment of the serious lung condition.
Treatment for advanced stages of the lung ailment typically includes a lung transplant.
Goulet, who reportedly has been on a ventilator since being admitted to the hospital last week, previously overcame a prostate cancer scare in the early 1990s.
The noted singer, who once counted late crooner Frank Sinatra as one of his many admirers, burst onto the international scene in 1960 when he performed in the popular Broadway musical "Camelot." He has won a Grammy, a Tony and an Emmy.
Dendreon Receives European Patent Covering PROVENGE(R) and Company's ...
SEATTLE, Jan. 15 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced that the company has been granted a broad European patent covering the company's lead product candidate PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. European patent No. 0 870 022 B1 covers the composition of matter of PROVENGE as well as the company's other active cellular immunotherapy (ACI) product candidates, such as NEUVENGE(TM) (lapuleucel-T), which utilize Dendreon's Antigen Delivery Cassette(TM) technology. The patent also covers methods of activating antigen presenting cells in vitro with certain fusion proteins developed by Dendreon, including the fusion protein that is used in PROVENGE. "The approval of this broad patent covering PROVENGE and our other active cellular immunotherapies in Europe is an important milestone for the company," stated Mitchell H.
|
